Related Experiment Video

Updated: Mar 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study

Robert Lins1, Yves Haerden2, Caroline de Vries3

  • 1University of Antwerpen, Hazelarenstraat 7, Antwerpen, 2020, Belgium. robert@linsconsulting.be.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|January 7, 2017
PubMed

Insights

Switching to barnidipine from other calcium channel blockers effectively lowers blood pressure in hypertensive patients. This study highlights barnidipine as a valuable option, particularly when tolerability is a concern for managing hypertension.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a leading global cause of cardiovascular disease.
  • Calcium channel blockers (CCBs) are effective antihypertensives, but tolerability issues limit their use in some patients.
  • Uncontrolled hypertension remains a significant clinical challenge.

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of barnidipine in patients with mild to moderate hypertension who switched from other CCBs.
  • To assess barnidipine's real-world performance in a clinical setting.

Main Methods:

  • A subgroup analysis from the prospective BASIC-HT study.
  • 1710 patients switched from amlodipine or lercanidipine to barnidipine (monotherapy or combination therapy).
  • Tolerability and blood pressure were assessed over a 3-month follow-up period.

Main Results:

  • Mean systolic blood pressure decreased from 153.15 mmHg to 139.20 mmHg.
  • Mean diastolic blood pressure decreased from 88.85 mmHg to 81.56 mmHg.
  • 65.4% of patients switched due to tolerability issues with previous CCBs; edema was the main adverse event (4.8%).

Conclusions:

  • Barnidipine is a valuable therapeutic option for patients with mild to moderate hypertension.
  • Switching to barnidipine is particularly beneficial for patients experiencing tolerability issues with other CCBs.
  • Real-world data support barnidipine's efficacy and acceptable tolerability profile.
Abstract

Keywords:
BarnidipineCalcium channel blockersHypertensionObservational studyTreatment switch

More Related Videos

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.9K

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
303
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320